BioMarin Announces Third Quarter 2015 Financial Results and Company Update
29. Oktober 2015 16:03 ET
|
BioMarin Pharmaceutical Inc.
- Vimizim Net Product Revenue $65 million in the Quarter; Vimizim Full-year Revenue Guidance Increased to $220 to $235 million - Full-year Total BioMarin Revenue Guidance Increased to $880 million...